Conferences - Results from #7940

ASCO 2018: Sipuleucel-T OS and Clinical Outcomes by Baseline PSA Quartiles in Patients with mCRPC: PROCEED Registry June 4, 2018

ASCO 2018: Bladder Cancer and Germ Cell Tumors June 4, 2018

ASCO 2018: Immunotherapy in Prostate Cancer: The Path Forward June 4, 2018

ASCO 2018: Optimal Integration of PARP Inhibitors for Prostate Cancer: Which Test, Which Patient, and Which Therapy? June 4, 2018

ASCO 2018: Nonimmunotherapy Strategies in Advanced Bladder Cancer June 4, 2018

ASCO 2018: Radiopharmaceuticals: Emitting the Right Signals in Prostate Cancer June 4, 2018

ASCO 2018: Science of Oncology Award Lecture: Preventing HPV-Associated Cancers by Vaccination June 4, 2018

ASCO 2018: Optimizing Systemic Therapy in Advanced Renal Cell Carcinoma June 4, 2018

ASCO 2018: Patient-reported Outcomes in IMmotion151: Atezolizumab + Bevacizumab vs Sunitinib in Treatment Naive mRCC June 4, 2018

ASCO 2018: Updated Phase 1 Data Announced for Enfortumab Vedotin in Patients with Locally Advanced or Metastatic Urothelial Cancer Previously Treated with Checkpoint Inhibitor Therapy June 4, 2018

ASCO 2018: Abiraterone Acetate and Prednisone, AAP Plus Degarelix, and Degarelix Alone for Patients with Biochemically-Recurrent Prostate Cancer Following Radical Prostatectomy June 4, 2018

ASCO 2018: A phase II Study Investigating the Safety and Efficacy of Neoadjuvant Atezolizumab in Muscle Invasive Bladder Cancer (ABACUS) June 4, 2018

ASCO 2018: Preoperative Pembrolizumab Before Radical Cystectomy for Muscle-Invasive Urothelial Bladder Carcinoma: Interim Clinical and Biomarker Findings from the Phase 2 PURE-01 Study June 4, 2018

ASCO 2018: Biochemical Recurrence: Judicious Clinical Management of an Evolving Disease State June 4, 2018

ASCO 2018: KEYNOTE-046: ADXS-PSA Plus Pembrolizumab in Metastatic Castration-Resistant Prostate Cancer June 3, 2018

ASCO 2018: RESORT - A Randomized, Open Label, Multicenter Phase 2 Study, to Evaluate the Efficacy of Sorafenib in Patients with mRCC after a Radical Resection of the Metastases June 3, 2018

ASCO 2018: Patient Preference Between Darolutamide and Enzalutamide in Men with Metastatic Castration-resistant Prostate Cancer: ODENZA June 3, 2018

ASCO 2018: Precision Risk Stratification and Treatment in Biochemical-Recurrent Prostate Cancer June 3, 2018

ASCO 2018: Lifting the Veil on Micrometastatic Disease: Emerging Imaging Strategies in Biochemical Recurrence June 3, 2018

ASCO 2018: Sunitinib Alone Shows Non-inferiority Versus Standard of Care in mRCC - The CARMENA Study June 3, 2018

Page 398 of 616